Sep 2019 |
Finalised |
Preparatory work carried out by EURL ECVAM before the start of the validation study between November 2017 and September 2019. During this phase, intellectual property was addressed, legal agreements with method developer, test system supplier and EU-NETVAL laboratory were established and adequate training of the EU-NETVAL laboratory was ensured. An outline protocol describing the current status of the method, the quality controlled test system and reference and control items were made available to EU-NETVAL. OECD Good In Vitro Method Practices (GIVIMP, OECD, 2018) has been used as guidance. |
OECD Good In Vitro Method Practices (GIVIMP, OECD, 2018) |
Oct 2019 |
Finalised |
Start of the EURL ECVAM coordinated validation study. EU-NETVAL facility 'Accelera Srl (Italy)' agreed to develop one method from available published methods and to assess the method. |
EU-NETVAL |
Feb 2021 |
Finalised |
Final selection of the validation set chemicals to be used in the thyroid validation study PART 2. Selection was based on the advice provided by 15 experts in in vitro, in vivo and clinical thyroid disruption during an expert meeting in November 2019. |
|
Jun 2021 |
Finalised |
Completion of method definition and description prior to experimental assessment. |
|
Oct 2021 |
Finalised |
PART 1: Assessment of method robustness, reliability and within laboratory reproducibility using few test items. |
|
Feb 2023 |
Finalised |
PART 2: Assessment of the method's mechanistic relevance using selected validation set chemicals covering the underlying mechanism of this method. |
|
Aug 2023 |
Finalised |
The OECD Thyroid Disruption Methods Expert Group (TDM-EG) assessed the available data and study reports from EU-NETVAL, and provided its recommendation for further validation of the method. The method gives reproducible results. In case of further validation testing of more negative chemicals is necessary to confirm its specificity and the between laboratory reproducibility will need to be confirmed. |
Assessment reports by the OECD thyroid disruption methods expert group
|